Why consider vaginal drug administration?

被引:190
作者
Alexander, NJ
Baker, E
Kaptein, M
Karck, U
Miller, L
Zampaglione, E
机构
[1] Organon Pharmaceut USA Inc, Roseland, NJ 07068 USA
[2] UMD, New Jersey Med Sch, Newark, NJ USA
[3] Organon Int Inc, Roseland, NJ USA
[4] Stuttgart Womens Hosp, Stuttgart, Germany
[5] Univ Washington, Sch Med, Seattle, WA 98195 USA
关键词
intravaginal administration; vaginal rings; contraceptives; hormone therap;
D O I
10.1016/j.fertnstert.2004.01.025
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To review the anatomy and physiology of the vagina, the merits of vaginal drug administration, and the currently available vaginal drug-administration systems. Design: Review of basic and clinical research. Result(s): Although clinicians commonly use topically administered drugs in the vagina, this route for systemic drug administration is somewhat novel. Experience with a variety of products demonstrates that the vagina is a highly effective site for drug delivery, particularly in women's health. The vagina is often an ideal route for drug administration because it allows for the administration of lower doses, steady drug levels, and less frequent administration than the oral route. With vaginal drug administration, absorption is unaffected by gastrointestinal disturbances, there is no first-pass effect, and use is discreet. Knowledge of anatomy, physiology, histology, and immunology of the vagina should allow clinicians to reassure their patients concerning this mode of delivery. Greater understanding and experience by clinicians should lead to increased use and acceptance of the vagina as a route for drug administration. Conclusion(s): The safety and efficacy of vaginal administration have been well established. The vaginal route of drug delivery is acceptable and may even be a preferable route of administration for many drugs, particularly hormones, whether for contraception or postmenopausal estrogen therapy. (C) 2004 by American Society for Reproductive Medicine.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 113 条
[1]   Indomethacin for preterm labor: A randomized comparison of vaginal and rectal-oral routes [J].
Abramov, Y ;
Nadjari, M ;
Weinstein, D ;
Ben-Shachar, I ;
Plotkin, V ;
Ezra, Y .
OBSTETRICS AND GYNECOLOGY, 2000, 95 (04) :482-486
[2]   OVARIAN-FUNCTION, BLEEDING CONTROL AND SERUM-LIPOPROTEINS IN WOMEN USING CONTRACEPTIVE VAGINAL RINGS RELEASING 5 DIFFERENT PROGESTINS [J].
AHREN, T ;
VICTOR, A ;
LITHELL, H ;
VESSBY, B ;
JACKANICZ, TM ;
JOHANSSON, EDB .
CONTRACEPTION, 1983, 28 (04) :315-327
[3]   CLINICAL-PERFORMANCE AND ENDOCRINE PROFILES OF CONTRACEPTIVE VAGINAL RINGS RELEASING 3-KETO-DESOGESTREL AND ETHINYLESTRADIOL [J].
APTER, D ;
CACCIATORE, B ;
STENMAN, UH ;
ALAPIESSA, U ;
ASSENDORP, R .
CONTRACEPTION, 1990, 42 (03) :285-295
[4]  
*ARD BIOSC LTD, 2003, INT BIOT CONV EXH S
[5]   Further data favoring the hypothesis of the uterine first-pass effect of vaginally administered micronized progesterone [J].
Balasch, J ;
Fabregues, F ;
Ordi, J ;
Creus, M ;
Penarrubia, J ;
Casamitjana, R ;
Manau, D ;
Vanrell, CA .
GYNECOLOGICAL ENDOCRINOLOGY, 1996, 10 (06) :421-426
[6]   A CONTRACEPTIVE VAGINAL RING RELEASING NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL [J].
BALLAGH, SA ;
MISHELL, DR ;
LACARRA, M ;
SHOUPE, D ;
JACKANICZ, TM ;
EGGENA, P .
CONTRACEPTION, 1994, 50 (06) :517-533
[7]   Safety of single daily use for one week of C31G HEC gel in women [J].
Ballagh, SA ;
Baker, JM ;
Henry, DM ;
Archer, DF .
CONTRACEPTION, 2002, 66 (05) :369-375
[8]   Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol [J].
Bjarnadóttir, RI ;
Tuppurainen, M ;
Killick, SR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (03) :389-395
[9]   PRELIMINARY-REPORT OF UNEXPECTED LOCAL REACTIONS TO A PROGESTOGEN-RELEASING CONTRACEPTIVE VAGINAL RING [J].
BOUNDS, W ;
SZAREWSKI, A ;
LOWE, D ;
GUILLEBAUD, J .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 48 (02) :123-125
[10]   Ovarian function during use of vaginal rings delivering three different doses of Nestorone® [J].
Brache, V ;
Mishell, DR ;
Lahteenmaki, P ;
Alvarez, F ;
Elomaa, K ;
Jackanicz, T ;
Faundes, A .
CONTRACEPTION, 2001, 63 (05) :257-261